Diabetic Nephropathy Market and Forecast Analyst to 2025

  • ID: 3797413
  • Drug Pipelines
  • 207 pages
  • Datamonitor Healthcare
1 of 3
Disease Overview

Diabetic nephropathy, also known as diabetic kidney disease, is caused by damage to small blood vessels which can cause the kidneys to be less efficient in their blood filtration role or to fail altogether. The disease is a clinical syndrome characterized by albuminuria, decline in glomerular filtration rate, and elevated arterial blood pressure. Up to 50% of diabetics with a disease duration of over 20 years have diabetic nephropathy.

Market Snapshot
  • SGLT-2 inhibitor label indications and data for a cardiovascular benefit will spur use in DN patients.
  • Survey of 216 physicians in the US, Japan, and five major EU markets sheds light on prescribing patterns.
  • In parallel with diabetes, an increase in the prevalence burden of diabetic nephropathy cases is expected during 2017-37.
  • In-depth analysis of drug classes used for the treatment of diabetic nephropathy in the US, Japan, and five major EU markets.
  • Drugs with a cardiovascular benefit will have an advantage in diabetic nephropathy.
Note: Product cover images may vary from those shown
2 of 3
FORECAST: DIABETIC NEPHROPATHY (Published on 17 February 2017)
EXECUTIVE SUMMARY
MARKET OVERVIEW AND TRENDS
MARKET DEFINITION AND METHODOLOGY
ATRASENTAN
FARXIGA (DAPAGLIFLOZIN) FRANCHISE
FINERENONE
INVOKANA (CANAGLIFLOZIN) FRANCHISE
JARDIANCE (EMPAGLIFLOZIN) FRANCHISE
PRIMARY RESEARCH METHODOLOGY

TREATMENT: DIABETIC NEPHROPATHY (Published on 05 February 2018)
EXECUTIVE SUMMARY
PRIMARY RESEARCH METHODOLOGY
DISEASE DEFINITION AND DIAGNOSIS
PATIENT SEGMENTATION
GUIDELINE RECOMMENDATIONS
PRESCRIBING TRENDS

EPIDEMIOLOGY: DIABETIC NEPHROPATHY (Published on 05 February 2018)
EXECUTIVE SUMMARY
DISEASE BACKGROUND
METHODOLOGY
FORECAST
BIBLIOGRAPHY
APPENDIX: ADDITIONAL SOURCES

MARKETED DRUGS: DIABETIC NEPHROPATHY (Published on 02 February 2018)
EXECUTIVE SUMMARY
ACE INHIBITORS
ANGIOTENSIN II RECEPTOR BLOCKERS

PIPELINE: DIABETIC NEPHROPATHY (Published on 02 February 2018)
EXECUTIVE SUMMARY
CLINICAL PIPELINE OVERVIEW
TARGET PRODUCT PROFILE
CLINICAL TRIAL DESIGN
PRODUCT PROFILE (LATE STAGE): FARXIGA
PRODUCT PROFILE (LATE STAGE): INVOKANA
PRODUCT PROFILE (LATE STAGE): JARDIANCE
PRODUCT PROFILE (LATE STAGE): ATRASENTAN
PRODUCT PROFILE (LATE STAGE): FINERENONE

List of Figures
Figure 1: Diabetic nephropathy novel treatment market sales across the US, Japan, and five major EU markets, by country, 2016-25
Figure 2: Diabetic nephropathy sales of specific drug franchises across the US, Japan, and five major EU markets, 2025
Figure 3: Diabetic nephropathy novel treatment market sales in the US, 2016-25
Figure 4: Diabetic nephropathy novel treatment market sales in the five major EU markets, by country, 2016-25
Figure 5: Methodology flow for diabetic nephropathy
Figure 6: Price sources and calculations, by country
Figure 7: Atrasentan sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2016-25
Figure 8: Farxiga franchise sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2016-25
Figure 9: Finerenone sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country 2016-25
Figure 10: Invokana franchise sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2016-25
Figure 11: Jardiance franchise sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2016-25
Figure 12: Percentage of incident end-stage renal disease patients with diabetes as the primary cause
Figure 13: Patient segmentation by albuminuria and glomerular filtration rate, with US prevalence and risk of kidney outcomes
Figure 14: Type 2 diabetic patients receiving antihypertensives for treatment of diabetic nephropathy according to stage of renal impairment, by country
Figure 15: Type 2 diabetic patients receiving RAAS inhibitors for treatment of diabetic nephropathy according to stage of renal impairment, by country
Figure 16: Usage of ACE inhibitors, ARBs, and renin inhibitors for diabetic nephropathy, as a percentage of antihypertensives, among type 2 diabetics, by country
Figure 17: Antihypertensive monotherapy versus combination therapy used to treat diabetic nephropathy in type 1 and type 2 diabetics, by country
Figure 18: Antihypertensive monotherapy vs combination therapy used to treat diabetic nephropathy in type 2 diabetics, b renal impairment stage and country
Figure 19: Percentage of type 2 diabetic patients receiving antidiabetics according to stage of renal impairment, by country
Figure 20: Percentage of type 2 diabetic patients receiving metformin/selected fixed-dose combinations according to stage of renal impairment, by country
Figure 21: Percentage of type 2 diabetic patients receiving DPP-IV inhibitors (including metformin fixed-dose combinations), by stage of renal impairment and country
Figure 22: Ratio of prescribing of Januvia and Tradjenta in each stage of renal impairment compared to prescribing in patients without diabetic nephropathy, by country
Figure 23: Percentage of type 2 diabetic patients receiving SGLT-2 inhibitors (excluding fixed-dose combinations) according to stage of renal impairment, by country
Figure 24: Percentage of type 2 diabetic patients receiving GLP-1 agonists and fixed-ratio combinations with insulin, by stage of renal impairment and country
Figure 25: Percentage of type 2 diabetic patients receiving any insulin according to stage of renal impairment, by country
Figure 26: Percentage of type 2 diabetic patients receiving any insulin according to stage of renal impairment, PCPs only, by country
Figure 27: Percentage of type 2 diabetic patients receiving sulfonylureas according to stage of renal impairment, by country
Figure 28: Compliance rates of type 2 diabetics with antidiabetic medications according to renal impairment stage, by country
Figure 29: Trends in total prevalent cases of diabetic nephropathy in the US, Japan, and five major EU markets, by country, 2017-37
Figure 30: Farxiga for diabetic nephropathy - SWOT analysis
Figure 31: Drug assessment summary for Farxiga in diabetic nephropathy
Figure 32: Drug assessment summary for Farxiga in diabetic nephropathy
Figure 33: Invokana for diabetic nephropathy - SWOT analysis
Figure 34: Drug assessment summary for Invokana in diabetic nephropathy
Figure 35: Drug assessment summary for Invokana in diabetic nephropathy
Figure 36: Jardiance for diabetic nephropathy - SWOT analysis
Figure 37: Drug assessment summary for Jardiance in diabetic nephropathy
Figure 38: Drug assessment summary for Jardiance in diabetic nephropathy
Figure 39: Atrasentan for diabetic nephropathy - SWOT analysis
Figure 40: Drug assessment summary for atrasentan in diabetic nephropathy
Figure 41: Drug assessment summary for atrasentan in diabetic nephropathy
Figure 42: Finerenone for diabetic nephropathy - SWOT analysis
Figure 43: Drug assessment summary for finerenone in diabetic nephropathy
Figure 44: Drug assessment summary for finerenone in diabetic nephropathy

List of Tables
Table 1: Patient self-reported cardiovascular disease in the diabetic nephropathy and general diabetes populations in the US
Table 2: Summary of drug classes and molecules included in the diabetic nephropathy patient-based forecast
Table 3: Patent expiries occurring in diabetic nephropathy during the forecast period, 2016-25
Table 4: Exchange rates used for calculating prices
Table 5: Atrasentan sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 6: Farxiga franchise sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 7: Finerenone sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 8: Invokana franchise sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 9: Jardiance franchise sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 10: Diabetologists, endocrinologists, and nephrologists surveyed for the diabetic nephropathy primary research study, 2016
Table 11: Primary care physicians, diabetologists, and endocrinologists surveyed for the diabetic nephropathy primary research study, 2017
Table 12: Guideline recommendations for blood pressure and glycemic control - kidney organizations
Table 13: Guideline recommendations for blood pressure and glycemic control - diabetes organizations
Table 14: Risk of cardiovascular death and end-stage renal disease according to albuminuria and eGFR (% per year)
Table 15: Proportion of US patients with diabetic nephropathy who are treated with antihypertensives/RAAS inhibitors, by renal stage
Table 16: Sources used for diabetic nephropathy analysis in the US, Japan, and five major EU markets, by country
Table 17: Age-standardized diabetic nephropathy prevalence proportions, by country
Table 18: Segmentation of diabetic nephropathy into chronic kidney disease stage
Table 19: Total prevalent cases of diabetic nephropathy in the US, Japan, and five major EU markets, by country, 2017-37
Table 20: ACE inhibitors class overview
Table 21: ARBs class overview
Table 22: Major ARB trials in type 2 diabetic nephropathy patients with severe albuminuria
Table 23: Phase III pipeline products in development for diabetic nephropathy
Table 24: Cozaar drug profile
Table 25: Cozaar pivotal trial data in diabetic nephropathy
Table 26: Farxiga drug profile
Table 27: Farxiga Phase III trial in chronic kidney disease, including diabetic nephropathy
Table 28: Farxiga Phase III trial in type 2 diabetes with cardiovascular disease or multiple risk factors (includes diabetic nephropathy patients)
Table 29: Farxiga Phase II/III trial on UACR and glycemic control in diabetic nephropathy
Table 30: Invokana drug profile
Table 31: Invokana Phase III trial in diabetic nephropathy
Table 32: Jardiance drug profile
Table 33: Atrasentan drug profile
Table 34: Atrasentan Phase III trial in diabetic nephropathy
Table 35: Atrasentan Phase IIb pooled results of 12-week studies in diabetic nephropathy
Table 36: Finerenone drug profile
Table 37: Finerenone Phase III trials in diabetic nephropathy
Table 38: Finerenone Phase IIb (ARTS-DN) results in diabetic nephropathy
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll